Review Article

Extranodal NK T-cell lymphoma, nasal type: New staging system and treatment strategies
Tae Min Kim1,2 and Dae Seog Heo1,2,3
1Department

of Internal Medicine, Seoul National University Hospital; 2Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea

(Received July 12, 2009 Revised August 05, 2009 Accepted August 10, 2009 Online publication September 16, 2009)

Extranodal NK T-cell lymphoma (NTCL) is characterized by clinical heterogeneity based on clinical prognostic factors and survival outcome. NTCL subsets are classied as upper aerodigestive tract (UAT) NTCL or non-UAT NTCL; non-UAT has pathologic similarity to UAT-NTCL but is a clinically distinct subtype. Due to the clinical heterogeneity of NTCL, optimal treatment modalities and prognostic factors have been difcult to determine. Ann Arbor staging for lymphomas and the International Prognostic Index (IPI) have been used to predict prognosis for UAT-NTCL; however, local tumor invasiveness (bony invasion or perforation or invasion of the overlying skin) is the most signicant factor for poor outcomes in localized UAT-NTCL. Thus, a new staging system is proposed: limited disease (stage I II UAT-NTCL without local tumor invasiveness) and extensive disease (stage I II with local invasiveness or stage III IV disease of UAT NTCL, and non-UAT NTCL) based on treatment outcomes. NTCL is resistant to anthracyclinebased chemotherapy, whereas non-anthracycline combination chemotherapy (such as ifosfamide, methotrexate, etoposide, and prednisolone) has an activity against NTCL as either a front-line or as a second-line treatment. The effectiveness of radiotherapy is evident in limited disease, but questionable in extensive disease. (Cancer Sci 2009; 100: 22422248)

Subtypes of NK T-Cell Lymphoma

xtranodal natural killer (NK) T-cell lymphoma, nasal type (NTCL) is characterized by angioinvasion, prominent necrosis, a cytotoxic phenotype and a strong association with EpsteinBarr virus (EBV).(1,2) The Hong Kong workshop participants initially dened the clinical, phenotypic, and genotypic features of NTCL as having a distinct clinicopathologic entity,(3) which was claried by World Health Organization (WHO) classication.(1,2) NTCL frequently destroys the facial midline of the upper aerodigestive tract (UAT) and spreads to or relapses at extranodal sites including skin, gastrointestinal tract, bone marrow, lung, extremities, orbit, adrenal gland, testis, or the central nervous system.(13) NTCL is very rare in Western populations but relatively common among Asians, Mexicans, and South Americans of American Indian descent.(3,4) It is also common in Korea, with a marked preponderance of the NK cell phenotype, comprising up to 8.7% to 10.5% of all nonHodgkins lymphomas (NHLs) and 74.1% of lymphomas arising in the nasal cavity and paranasal sinuses.(5,6) Due to the clinical heterogeneity and various prognostic factors of NTCL,(710) subtypes have been variously described as: nasal versus nasal-type,(1,3) nasal versus non-nasal,(11) UAT versus non-UAT,(7) and nasal (UAT) versus extranasal.(2,9) One group attempted to further divide UAT disease into nasal and Waldeyer ring NTCL based on a clinical heterogeneity of this subtype.(10) In this review, we focus on the subsets based on treatment outcomes.
Cancer Sci | December 2009 | vol. 100 | no. 12 | 22422248

Nasal NTCLs were initially dened as those involving the nasal region, while nasal-type (or extranasal) NTCLs were dened as those involving the entire UAT as well as non-UAT regions, including the skin, gastrointestinal tract, and testis.(1,3) Differences between clinical prognostic factors were not observed between nasal and nasal-type UAT lymphoma, whereas treatment outcomes and clinical parameters differed signicantly between UAT and non-UAT lymphomas (Fig. 1 and Table 1).(12,13) Although NTCL subtypes share identical morphology, phenotype, and genotype,(13) clinical differences were observed during the International Peripheral T-cell Lymphoma Project(9) and the Korean Cancer Study Group study.(7) Upper aerodigestive tract NK T-cell lymphoma. UAT-NTCL was dened as a primary tumor involving nasal UAT (nasal cavity or nasopharynx) or the extra-nasal UAT (oral cavity, oropharynx, or hypopharynx), regardless of dissemination to other sites. Comparable survival outcomes were observed between nasal and extra-nasal UAT-NTCLs (5-year overall survival [OS] 41% vs 41%, respectively; and 5-year progressionfree survival [PFS] 33% vs 38%, respectively), whereas regional lymphadenopathy and advanced stage were signicantly higher in patients with extra-nasal UAT-NTCL than in those with nasal UAT-NTCL. Hemophagocytosis, a common complication in NTCL (28% of patients),(7,14,15) reduced survival time in patients with UAT- and non-UAT-NTCL. Recently, Li et al.(8) revealed distinct clinical features of Waldeyer ring-NTCL and compared clinical presentations of nasal and Waldeyer ring-NTCLs.(10) Patients with Waldeyer ring-NTCL demonstrated a higher propensity for nodal involvement, advanced stage disease, intermediate chemosensitivity, and favorable prognosis. In particular, nodal involvement was found to be signicantly higher in Waldeyer ring lymphoma (8082%) compared to nasal NTCL (17%) in Chinese studies.(8,10) These ndings differ somewhat from results of other studies, which found that 17% to 46% of NTCLs exhibited regional lymph node involvement.(7,1619) Nevertheless, nasal and Waldeyer ring lymphomas still represent a clinical heterogeneity within the UAT-NTCL category,(10) thus, for a risk-stratied treatment approach, it is crucial to classify subtypes based on the prognostic factors. Non-upper aerodigestive tract NK T-cell lymphoma. Non-UAT (NUAT)-NTCL corresponds to a primary tumor outside the UAT, in places such as the skin, gastrointestinal tract, bone marrow, lung, extremities, orbit, adrenal gland, testis, or central nervous system.(7) NUAT-NTCL is associated with signicantly higher proportions of advanced stage disease, two or more extranodal sites, elevated lactate dehydrogenase (LDH) levels,
3To

whom correspondence should be addressed. E-mail: heo1013@snu.ac.kr

doi: 10.1111/j.1349-7006.2009.01319.x 2009 Japanese Cancer Association

Fig. 1.

KaplanMeier plots of (A) overall survival and (B) progression-free survival according to the disease subtypes.

B symptoms (e.g., fever, night sweats, weight loss), and poor performance status (Table 1).(7) Similar ndings were obtained from a nationwide survey in Japan(20) and from the International Peripheral T-cell Lymphoma Project.(9) Korean patients with NUAT-NTCL exhibited more B symptoms and bone marrow involvement than those with UAT-NTCL; however, the International Peripheral T-cell Lymphoma Project did not nd these differences. Although advanced stage was associated with survival time in a few studies,(19,21) other studies failed to demonstrate the predictive value of the Ann Arbor staging system,(7,9,22) and the Ann Arbor stages III IV were not signicantly associated with shortened survival time in NUAT disease in our study.(7) The IPI score also failed to distinguish between low-intermediate and high-intermediate risk groups in NUAT disease (2-year OS 25% vs 36%, respectively; P = 0.520).(7) Furthermore, the IPI score was not found to affect survival of extranasal NTCL in the International Peripheral T-cell Lymphoma Project (IPI score 01 vs IPI score 45 for 5-year OS, 17% vs 20%).(23) Although still used in the 2008 WHO Classication of Tumours of Haematopoietic and Lymphoid Tissues,(2) the term nasal-type or extranasal was originally dened by the Hong Kong workshop(3) and included in the 2001 WHO classication(1) is ambiguous (Fig. 2). That is, extranasal NTCL refers to either a tumor outside the nasal region according to the 2001 WHO classication or a tumor outside the UAT according to the 2008 WHO classication. Consequently, other designations (e.g., NUAT) are appropriate than extranasal or nasal-type
Table 1.

NTCL. Taken together, these ndings demonstrate that NUAT NTCL is a distinct subtype compared to UAT-NTCL.
Prognostic Factors of Upper Aerodigestive Tract NK T-Cell Lymphoma
Ann Arbor staging. The utility of Ann Arbor staging as a predictor of prognosis in nasal lymphoma is unclear. In early reports regarding nasal lymphoma, multivariate analysis revealed that only Ann Arbor stage I was positively associated with survival (5-year OS, 66%); however, immunophenotyping was performed only in 45% of patients (T-cell, 78%).(16) A study of NHL of the nose and nasopharynx also showed that Ann Arbor stage was an independent prognostic factor for survival (NK T-cell, 45%).(17) Similarly, Ann Arbor stage was a signicant factor for survival in patients with early-stage nasal NTCL (5-year OS, 4278% for stage I and 1946% for stage II).(14,24) Furthermore, univariate analysis revealed that advanced stage had marginal signicance as a predictor of survival.(9) However, an Italian survey found no signicant differences between early-stage and advanced diseases in the complete remission (CR) rate or in survival rates.(25) In addition, the Ann Arbor staging system did not predict survival in Korean patients with early-stage disease (5-year OS 56% for stage I vs 44% for stage II).(26,27) This nding was consistent with results from patients with early-stage UAT-NTCL by Korean multicenter study.(7) Because inltrative nature is not considered in Ann Arbor staging system, the predictive role of the staging system

Comparison of clinical parameters between the NK T-cell lymphoma subtypes Korean Cancer Study Group UAT Non-UAT 59 (21) 59 42 59 44 66 12 58 42 22 P 0.244 0.199 <0.001 <0.001 <0.001 0.188 0.007 <0.001 <0.001 International Peripheral T-cell Lymphoma Project Nasal 92 (72) 64 52 27 16 45 3 39 9 10 Extranasal 35 (28) 66 45 68 55 60 3 54 37 14 P 1.000 0.670 <0.001 <0.001 0.009 1.000 0.161 <0.001 0.530

Patients, number (%) Male, % Median age, years Ann Arbor stage III IV, % Number of extranodal sites 2 Elevated LDH, % Hemophagocytosis, % B symptoms, % ECOG performance status 2, % Bone marrow involvement, %

221 (79) 67 47 15 17 38 7 38 18 3

ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; UAT, upper aerodigestive tract.

Kim and Heo

Cancer Sci | December 2009 | vol. 100 | no. 12 | 2243 2009 Japanese Cancer Association

Fig. 2. Anatomic boundary of NK T-cell lymphoma.

is limited in early-stage NTCL with extensively destructive lesions. International prognostic index (IPI). Although the IPI failed to predict survival in NTCL patients in a few studies,(14,27,28) most studies showed that low IPI score was associated with good prognosis for survival.(7,9,24,26,29,30) Low IPI scores (1) were signicantly associated with improved CR rate (77% vs 36%, P = 0.017) and 10-year OS (64% vs 27%, P = 0.003) compared to high IPI score (2) in nasal NTCL patients who received anthracycline-based chemotherapy.(29) Additionally, the IPI score or stage-modied IPI score independently predicted survival in early-stage UAT-NTCL.(24,26) Although the IPI score was able to identify four distinct risk groups with different median OS rates, it could not discriminate between high-intermediate and high-risk groups with UAT-NTCL (2-year OS 9% vs 17%, respectively; P = 0.361).(7) Furthermore, the distribution of patients was unbalanced, with most having low IPI scores, suggesting that including the IPI score in a prognostic model should be done cautiously.(19,20,26) Local tumor invasiveness. Paranasal extension based on T stage was initially identied as a prognostic factor in stage I II
(A) (B)

lymphomas of nasal cavity and paranasal sinuses.(31) Similarly, Logsdon et al.(32) reclassied stage I lymphomas of nasal cavity and paranasal sinuses into T stages based on the extent of disease, and demonstrated that T stage is the strongest predictor of outcome. Paranasal extension in NTCL was found to be a significant predictive factor for early-stage disease;(24,30) although one study showed no prognostic signicance of paranasal extension in stage I NTCL.(14) In another study, 21% of patients presented with local tumor invasiveness and all of these patients died earlier (median OS, 10.6 months; range, 1.464.8 months); local tumor invasiveness was dened as bony invasion or perforation or invasion of the overlying skin (Fig. 3AB).(26) Presence of local invasiveness reduced survival (5-year OS 4% vs 68%, P < 0.001 [Fig. 3C]; and 1-year disease-free survival 13% vs 68%, P < 0.001 [Fig. 3D]) in both the combined modality group and in the chemotherapy only group. Local tumor invasiveness has been shown to be the most important prognostic factor in predicting low probability of CR and reduced survival in stage I II UAT-NTCL.(26) Therefore, local invasiveness should be taken into consideration to the selection of treatment modalities in early-stage UAT-NK T-cell lymphoma.

(C)

(D)

Fig. 3. Local tumor invasiveness (LTI) included (A) thinning of right medial wall of maxillary bone (arrow) in CT of paranasal sinuses and (B) palatal perforation. KaplanMeier plots of (C) overall survival and (D) disease-free survival according to the local tumor invasiveness.

2244

doi: 10.1111/j.1349-7006.2009.01319.x 2009 Japanese Cancer Association

NTCL prognostic index. A Korean retrospective study developed a prognostic model for NTCL based on the following adverse factors: B symptoms, Ann Arbor stage, LDH level, and regional lymphadenopathy.(19) Four distinct risk groups were identied: group 1, no adverse factors (5-year OS, 81%); group 2, one factor (5-year OS, 64%); group 3, two factors (5-year OS, 34%); and group 4, three or more factors (5-year OS, 7%). This model was validated only in UAT-NTCL patients, not in nonUAT disease in the Korean Cancer Study Group survey(7) and International Peripheral T-cell Lymphoma Project.(9) Because multivariate analysis determined independent predictors for survival differed between each subtype,(7) a prognostic model should be developed for each subtype. Tumor biologic and microenvironmental factors. High Ki-67 nuclear antigen (65%) is a marker for actively proliferating tumor cells and is correlated with tumor bulk and adverse survival outcomes in stage I II UAT-NTCL.(27) Patients with nasal UAT-NTCL and high Ki-67 expression demonstrated worse survival outcomes. Histologically, high Ki-67 proliferation (>50%) or transformed tumor cells (>40%) had prognostic signicance for survival in nasal NTCL.(9) Because cyclooxygenase-2 (COX-2) promotes tumor proliferation, growth, and metastasis, its expression was also evaluated in early-stage NTCL.(33) COX-2 expression by tumor cells was associated with signicantly lower 2-year disease-free survival rates and 2-year systemic relapse-free survival rates. However, COX-2 positivity was not a signicant predictor of 5-year OS (28% vs 47%, P = 0.060).(33) NK cell receptors, including CD94, NKG2, and killer immunoglobulin-like receptors, have also been investigated as potential prognostic factors. Lin et al.(34) found that patients positive for CD94 expression more often survived beyond 1 year compared with those negative for CD94 expression (median OS 60 months vs 10 months, respectively; P = 0.026). Expression of anti-apoptotic proteins, such as activated caspase-3, granzyme B protease inhibitor 9 (PI9), and Bcl-2 proteins were analyzed in NTCL by the Groupe dEtude des Lymphomes de l Adulte
Table 2.

group.(35) Interestingly, high expression of PI9 by lymphoma cells was associated with a favorable outcome (5-year OS 64 9% vs 23 11%, P = 0.009). Additionally, PI9 expression independently predicted overall and event-free survivals in NTCL patients. Regarding EBV status, high copies of EBV DNA at presentation was the most signicant prognostic factor for reduced disease-free survival (median, 0.5 months vs >27.0 months, P = 0.025) and lower OS in NTCL.(36) Patients with bone marrow that is positive for EBV by in situ hybridization demonstrated signicantly poorer survival in early-stage NTCL.(37,38) Recently, our colleague hypothesized that tumor-inltrating regulatory T cells may suppress NTCL cells that have an activated NK cell phenotype, thereby contributing to a favorable outcome.(39) Low numbers of tumor-inltrating regulatory T cells, which is associated with poor performance status and non-UAT tumor, independently predicted worse survival. Furthermore, the number of tumor-inltrating regulatory T cells predicted survival independent of Ann Arbor stage, IPI score, or NTCL prognostic index. The positive rate of 18uoro-2-deoxyglucose positron emission tomography to detect a lymphoma lesion was 100% in NTCL.(40) Furthermore, pre-treatment maximal standardized uptake value was associated with local tumor invasiveness in NTCL of the head and neck, and predicted disease-specic survival.(41)
New Staging System and Treatment Strategies

Patients with UAT-NTCL have demonstrated superior outcomes compared to those with non-UAT NTCL (5-year OS 4142% vs 922%, respectively; Fig. 1).(7,23) Although patients with stage I II UAT-NTCL experienced favorable outcomes (5-year OS, 3777%),(10,18,24,26,30) local tumor invasiveness signicantly reduced survival and response regardless of treatment modality.(26) Based on these treatment outcomes, a new staging system for NTCL is proposed: limited disease (stage I II UAT-

New staging system for extranodal NK T-cell lymphoma, nasal type Limited disease Extensive disease Non-UAT presentation UAT presentation: Stage I II with local tumor invasiveness Stage III IV No Unfavorable Questionable

Category

UAT presentation: Stage I II without local tumor invasiveness

Long-term survival Prognosis Usefulness of radiotherapy UAT, upper aerodigestive tract. Table 3.

Yes Favorable Yes

Treatment outcomes of upper aerodigestive tract-NK T-cell lymphoma(7,26) Limited disease Extensive disease Stage I II UAT-NTCL with LTI 36% 65% 35% 0% 13% Unknown Stage III IV UAT-NTCL 17% 40% 60% 16% 52% No

Treatment outcomes

Stage I II UAT-NTCL without LTI 90% 34% 14% 79% 63% Yes

CR CRu rate Relapse failure Locoregional Systemic Survival outcome 2-year OS 2-year DFS Role of radiotherapy

CR CRu, complete remission CR unconrmed; DFS, disease-free survival; LTI, local tumor invasiveness; NTCL, NK T-cell lymphoma; OS, overall survival; UAT, upper aerodigestive tract.

Kim and Heo

Cancer Sci | December 2009 | vol. 100 | no. 12 | 2245 2009 Japanese Cancer Association

NTCL without invasiveness) and extensive disease (stage I II with local invasiveness or stage III IV disease of UAT NTCL, and non-UAT NTCL) based on treatment outcomes (Tables 2,3).(7,26) Limited disease. Due to high systemic failure rate after treatment with radiotherapy alone,(18) chemoradiation has been widely used in patients with localized NTCL.(24,26,30,42,43) However, anthracycline-based chemotherapy followed by radiation produced a CR rate of 58% and planned radiation was delivered in only 35% of patients due to early progression.(42) The role of early radiotherapy compared with initial chemotherapy was highlighted in a few studies.(24,30,43) Front-line use of radiotherapy produced superior survival compared to initial chemotherapy in localized nasal NTCL (5-year OS 83% vs 29%, respectively).(30) Li et al.(24) recommended a front-line radiotherapy for early-stage nasal NTCL and suggested that radiotherapy followed by chemotherapy should be considered for patients with adverse factors or stage II NTCL. In particular, high-dose radiotherapy (50 Gy) signicantly improved the 5-year local control rate patients with stage I nasal lymphoma compared with low-dose therapy (100% vs 67%, respectively; P = 0.013). Additional chemotherapy did not improve treatment outcomes in stage I nasal lymphoma.(44) Likewise, the addition of chemotherapy to radiotherapy in stage I nasal NTCL did not improve survival or response rate.(24) The benet of additional chemotherapy on survival was observed in early-stage Waldeyer ring NTCL, but not in early-stage nasal NTCL.(10) Due to the frequent expression of multidrug-resistance protein 1, anthracycline-based chemotherapy has limited activity against NTCL. Our study revealed that initial anthracycline-based combination chemotherapy resulted in a CR rate of 43% and a 2-year OS of 53% in stage I II UATNTCL.(45) Patients who achieved CR after initial chemotherapy did not benet from additional radiotherapy. Subsequent study of a nonanthracycline-based regimen (IMEP: combination chemotherapy of ifosfamide, methotrexate, etoposide, and prednisolone) demonstrated CR rates of 79% and 93% after initial IMEP alone and IMEP radiotherapy, respectively.(46) However, 64% of CR patients relapsed at local sites; these local failures were successfully treated with additional radiotherapy. Based on high local failure rate after IMEP chemotherapy alone, a phase II multicenter trial of IMEP followed by radiotherapy was initiated by the Korean Cancer Study Group (KCSG-LY04-03) in stage I II UATNTCL. This study is now closed with the planned numbers of patients registered and its results will be presented. Extensive disease. Although combined modality treatment (i.e., chemotherapy and radiotherapy) provided a superior outcome in stage I II UAT-NTCL with local tumor invasiveness compared to chemotherapy alone,(26) combined modality treatment has not been compared with radiotherapy alone. Furthermore, neither the role of radiotherapy nor the optimal sequence of chemotherapy and radiation have been veried in this disease subset with local invasiveness. Thus, various therapeutic interventions should be investigated in these patients to improve treatment outcomes. For patients with stage III IV UAT-NTCL, combination chemotherapy is considered to be the standard treatment; however, its prognosis is dismal.(47,48) An anthracycline-based regimen(45) and IMEP chemotherapy(46) were both disappointing in this group (CR rate of 13%; and median OS 2.7 months for patients treated with IMEP). Successful treatment outcomes were observed in refractory or relapsed NTCL using L-asparaginase alone(49) or in combination with other chemotherapy.(50,51) In addition, L-asparaginase demonstrated anti-tumor activity against NK cell lymphoma leukemia cells in vitro.(52) Thus, a phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide was conducted for patients with
2246

advanced, relapse, or refractory NTCL.(53) Of three patients with newly diagnosed advanced-stage NTCL, one patient achieved CR and one achieved partial remission. Because nuclear factorkappa B (NF-jB) is constitutively activated in NK leukemia lymphoma cells, NF-jB inhibitors were tested in vitro.(54) NF-jB inhibitors suppressed the growth of NK leukemia lymphoma cells by reducing constitutive NF-jB activation. Another study demonstrated that bortezomib induces apoptosis in NK cell leukemia lymphoma in vitro and in a preclinical animal model.(55) Based on these results, a phase I study of bortezomib plus cyclophosphamide, doxorubicin, vincristine, and prednisolone was undertaken with patients with advanced-stage T- or NK T-cell lymphoma.(56) Only one of three patients treated with this regimen achieved CR. Salvage treatment. L-asparaginase-based chemotherapy was delivered as a salvage treatment for refractory or relapsed NTCL.(53,57) Two of three patients with refractory or relapsed NTCL attained CR after L-asparaginase regimen and were alive at 15 months and 7 months, respectively.(53) One large retrospective study of L-asparaginase-based regimen demonstrated an overall response rate of 82% (CR, 56%; 5-year OS 67%).(57) In addition, salvage treatment signicantly prolonged the 5-year OS compared with the best supportive care alone (38% vs 0%, respectively; P < 0.001).(58) Salvage radiotherapy improved survival in relapsed stage III IV NTCL patients, whereas relapsed patients with stage I II NTCL did not benet from salvage chemotherapy. Hematopoietic stem cell transplantation (HSCT) does not seem to improve treatment outcomes for disseminated or early refractory NTCL. Allogeneic HSCT when used with reducedintensity regimen, is a favorable treatment option for advanced-stage NTCL patients.(59) Autologous HSCT at the rst CR showed a trend toward better OS compared with historic controls.(60) However, retrospective matched controlled study demonstrated no signicant difference in overall survival between the HSCT and control groups (median, not reached vs 43.5 months), although disease-specic survival rates at 5 years were signicantly higher in the HSCT group than in the control group in patients who achieved CR (87% vs 68%, P = 0.027).(61) The overall survival data from HSCT was not superior to recent chemotherapy without HSCT (3year OSs, 80.4% for limited disease patients and 60% for all patients treated with rst-line IMEP chemotherapy involvedeld radiotherapy).(46) Furthermore, treatment with IMEP and L-asparaginase showed 5-year OS in 80% of extensive disease NTCL patients in our series (TM Kim and DS Heo, unpublished data). Taken together, the role of HSCT or any other new treatment in NTCL should be investigated in a prospective randomized trial. Second-line IMEP chemotherapy was evaluated in our institution after the failure of anthracycline-based chemotherapy.(62) The overall response rate was 44% (CR rate, 38%) and median OS was 8.2 months (5-year OS, 25%). Locoregional (n = 1) or systemic relapse (n = 4) was observed in 42% (n = 5) of patients who achieved CR. This salvage regimen was well-tolerated and moderately effective for refractory or relapsed NTCL. Because NTCL cells that specically express interleukin-9 and its receptor were inhibited by neutralizing antibody, its signaling pathway can be a new target for NTCL.(63) Heat-shock protein 90 inhibitor induced NTCL cells having activated phsophatidylinositol-3 kinase Akt pathway to an apoptosis.(64) Thus, this pathway can be exploited as a new therapeutic target. Constitutive activation of signal transducer and activator of transcription 3 (STAT3) was observed in NTCL cells and STAT3 inhibition resulted in cell death induction.(65) Accordingly, STAT3 protein can be another therapeutic target in NK T-cell lymphoma.
doi: 10.1111/j.1349-7006.2009.01319.x 2009 Japanese Cancer Association

Concluding Remarks

A new staging system has been proposed based on treatment outcomes: limited disease (stage I II UAT-NTCL without local tumor invasiveness) and extensive disease (stage I II with local invasiveness or stage III IV disease of UAT NTCL, and non-UAT NTCL). Due to the limited numbers of well conducted trials, there is no consensus on treatment strategy. In our cohorts, non-anthracycline combination chemotherapy followed by radiotherapy is effective for limited
References
1 Chan JK, Jaffe ES, Ralfkiaer E. Extranodal NK T-cell lymphoma, nasal type. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC, 2001; 2047. 2 Chan JK, Quintanilla-Martinez L, Ferry JA, Peh S-C. Extranodal NK T-cell lymphoma, nasal type. In: Swerdlow SH, Campo E, Harris NL et al., eds. WHO Classication of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC, 2008; 2858. 3 Jaffe ES, Chan JK, Su IJ et al. Report of the workshop on nasal and related extranodal angiocentric T natural killer cell lymphomas. Denitions, differential diagnosis, and epidemiology. Am J Surg Pathol 1996; 20: 103 11. 4 Gaal K, Sun NC, Hernandez AM, Arber DA. Sinonasal NK T-cell lymphomas in the United States. Am J Surg Pathol 2000; 24: 15117. 5 Ko YH, Kim CW, Park CS et al. REAL classication of malignant lymphomas in the Republic of Korea: incidence of recently recognized entities and changes in clinicopathologic features. Hematolymphoreticular Study Group of the Korean Society of Pathologists. Revised European-American lymphoma. Cancer 1998; 83: 80612. 6 Kang YK, Kim BS, Kim TW et al. Clinicopathologic characteristics of Korean non-Hodgkins lymphomas based on REAL classication. Cancer Res Treat 1999; 31: 64152. 7 Kim TM, Lee SY, Jeon YK et al. Clinical heterogeneity of extranodal NK T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group. Ann Oncol 2008; 19: 147784. 8 Li YX, Fang H, Liu QF et al. Clinical features and treatment outcome of nasaltype NK T-cell lymphoma of Waldeyer ring. Blood 2008; 112: 305764. 9 Au WY, Weisenburger DD, Intragumtornchai T et al. Clinical differences between nasal and extranasal natural killer T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood 2009; 113: 39317. 10 Li YX, Liu QF, Fang H et al. Variable clinical presentations of nasal and Waldeyer ring natural killer T-cell lymphoma. Clin Cancer Res 2009; 15: 290512. 11 Kwong YL. Natural killer-cell malignancies: diagnosis and treatment. Leukemia 2005; 19: 218694. 12 Lee SY, Park K, Ryoo BY et al. Korean multicenter study of extranodal NK T-cell lymphoma: failure of Ann Arbor staging in predicting prognosis. Seoul, Korea: The 29th World Congress of the International Society of Hematology, 2002. 13 Lee J, Park YH, Kim WS et al. Extranodal nasal type NK T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratication of therapy. Eur J Cancer 2005; 41: 14028. 14 Cheung MM, Chan JK, Lau WH, Ngan RK, Foo WW. Early stage nasal NK T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys 2002; 54: 18290. 15 Cuadra-Garcia I, Proulx GM, Wu CL et al. Sinonasal lymphoma: a clinicopathologic analysis of 58 cases from the Massachusetts General Hospital. Am J Surg Pathol 1999; 23: 135669. 16 Liang R, Todd D, Chan TK et al. Treatment outcome and prognostic factors for primary nasal lymphoma. J Clin Oncol 1995; 13: 66670. 17 Cheung MM, Chan JK, Lau WH et al. Primary non-Hodgkins lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol 1998; 16: 707. 18 Kim GE, Cho JH, Yang WI et al. Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment. J Clin Oncol 2000; 18: 5463. 19 Lee J, Suh C, Park YH et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 2006; 24: 6128. 20 Oshimi K, Kawa K, Nakamura S et al. NK-cell neoplasms in Japan. Hematology 2005; 10: 23745.

stage disease, but new treatment strategy is needed for extensive stage disease.
Acknowledgments
We apologize to all of the authors whose work could not be included in this review due to limited space. This study was supported by grants from the Korea Research Foundation (KRF-2004-015-E00155) and from the Innovative Research Institute for Cell Therapy (A062260), Republic of Korea.

21 Lee J, Kim WS, Park YH et al. Nasal-type NK T cell lymphoma: clinical features and treatment outcome. Br J Cancer 2005; 92: 122630. 22 Ko YH, Cho EY, Kim JE et al. NK and NK-like T-cell lymphoma in extranasal sites: a comparative clinicopathological study according to site and EBV status. Histopathology 2004; 44: 4809. 23 Armitage J, Vose J, Weisenburger D. International peripheral T-cell and natural killer T-cell lymphoma study: pathology ndings and clinical outcomes. J Clin Oncol 2008; 26: 412430. 24 Li YX, Yao B, Jin J et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer T-cell lymphoma. J Clin Oncol 2006; 24: 1819. 25 Pagano L, Gallamini A, Trape G et al. NK T-cell lymphomas nasal type: an Italian multicentric retrospective survey. Ann Oncol 2006; 17: 794800. 26 Kim TM, Park YH, Lee SY et al. Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E) II(E) extranodal NK T-cell lymphoma, nasal type. Blood 2005; 106: 378590. 27 Kim SJ, Kim BS, Choi CW et al. Ki-67 expression is predictive of prognosis in patients with stage I II extranodal NK T-cell lymphoma, nasal type. Ann Oncol 2007; 18: 13827. 28 Aviles A, Diaz NR, Neri N, Cleto S, Talavera A. Angiocentric nasal T natural killer cell lymphoma: a single centre study of prognostic factors in 108 patients. Clin Lab Haematol 2000; 22: 21520. 29 Chim CS, Ma SY, Au WY et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood 2004; 103: 21621. 30 You JY, Chi KH, Yang MH et al. Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK) T-cell lymphoma: a single institute survey in Taiwan. Ann Oncol 2004; 15: 61825. 31 Robbins KT, Fuller LM, Vlasak M et al. Primary lymphomas of the nasal cavity and paranasal sinuses. Cancer 1985; 56: 8149. 32 Logsdon MD, Ha CS, Kavadi VS, Cabanillas F, Hess MA, Cox JD. Lymphoma of the nasal cavity and paranasal sinuses: improved outcome and altered prognostic factors with combined modality therapy. Cancer 1997; 80: 47788. 33 Shim SJ, Yang WI, Shin E et al. Clinical signicance of cyclooxygenase-2 expression in extranodal natural killer (NK) T-cell lymphoma, nasal type. Int J Radiat Oncol Biol Phys 2007; 67: 318. 34 Lin CW, Chen YH, Chuang YC, Liu TY, Hsu SM. CD94 transcripts imply a better prognosis in nasal-type extranodal NK T-cell lymphoma. Blood 2003; 102: 262331. 35 Bossard C, Belhadj K, Reyes F et al. Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK T-cell lymphoma: results of a Western series of 48 patients treated with rst-line polychemotherapy within the Groupe dEtude des Lymphomes de lAdulte (GELA) trials. Blood 2007; 109: 21839. 36 Au WY, Pang A, Choy C, Chim CS, Kwong YL. Quantication of circulating EpsteinBarr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood 2004; 104: 2439. 37 Huang WT, Chang KC, Huang GC et al. Bone marrow that is positive for EpsteinBarr virus encoded RNA-1 by in situ hybridization is related with a poor prognosis in patients with extranodal natural killer T-cell lymphoma, nasal type. Haematologica 2005; 90: 10639. 38 Lee J, Suh C, Huh J et al. Effect of positive bone marrow EBV in situ hybridization in staging and survival of localized extranodal natural killer T-cell lymphoma, nasal-type. Clin Cancer Res 2007; 13: 32504. 39 Kim WY, Jeon YK, Kim TM et al. Increased quantity of tumor-inltrating FOXP3-positive regulatory T cells is an independent predictor for improved clinical outcome in extranodal NK T-cell lymphoma. Ann Oncol 2009; doi: 10.1093/annonc/mdp056. 40 Kako S, Izutsu K, Ota Y et al. FDG-PET in T-cell and NK-cell neoplasms. Ann Oncol 2007; 18: 168590. 41 Suh C, Kang YK, Roh JL et al. Prognostic value of tumor 18F-FDG uptake in patients with untreated extranodal natural killer T-cell lymphomas of the head and neck. J Nucl Med 2008; 49: 17839.

Kim and Heo

Cancer Sci | December 2009 | vol. 100 | no. 12 | 2247 2009 Japanese Cancer Association

42 Kim WS, Song SY, Ahn YC et al. CHOP followed by involved eld radiation: is it optimal for localized nasal natural killer T-cell lymphoma? Ann Oncol 2001; 12: 34952. 43 Ribrag V, Ell Hajj M, Janot F et al. Early locoregional high-dose radiotherapy is associated with long-term disease control in localized primary angiocentric lymphoma of the nose and nasopharynx. Leukemia 2001; 15: 11236. 44 Shikama N, Izuno I, Oguchi M et al. Clinical stage IE primary lymphoma of the nasal cavity: radiation therapy and chemotherapy. Radiology 1997; 204: 46770. 45 Kim BS, Kim TY, Kim CW et al. Therapeutic outcome of extranodal NK T-cell lymphoma initially treated with chemotherapy result of chemotherapy in NK T-cell lymphoma. Acta Oncol 2003; 42: 77983. 46 Lee KW, Yun T, Kim DW et al. First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy + ) radiotherapy is active in stage I II extranodal NK T-cell lymphoma. Leuk Lymphoma 2006; 47: 127482. 47 Chan JK, Sin VC, Wong KF et al. Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood 1997; 89: 450113. 48 Kwong YL, Chan AC, Liang R et al. CD56+ NK lymphomas: clinicopathological features and prognosis. Br J Haematol 1997; 97: 821 9. 49 Nagafuji K, Fujisaki T, Arima F, Ohshima K. L-asparaginase induced durable remission of relapsed nasal NK T-cell lymphoma after autologous peripheral blood stem cell transplantation. Int J Hematol 2001; 74: 44750. 50 Yong W, Zheng W, Zhang Y et al. L-asparaginase-based regimen in the treatment of refractory midline nasal nasal-type T NK-cell lymphoma. Int J Hematol 2003; 78: 1637. 51 Yong W, Zheng W, Zhu J et al. Midline NK T-cell lymphoma nasal-type: treatment outcome, the effect of L-asparaginase based regimen, and prognostic factors. Hematol Oncol 2006; 24: 2832. 52 Ando M, Sugimoto K, Kitoh T et al. Selective apoptosis of natural killer-cell tumours by L-asparaginase. Br J Haematol 2005; 130: 8608. 53 Yamaguchi M, Suzuki R, Kwong YL et al. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK) T-cell lymphoma and leukemia. Cancer Sci 2008; 99: 101620.

54 Kim K, Ryu K, Ko Y, Park C. Effects of nuclear factor-kappaB inhibitors and its implication on natural killer T-cell lymphoma cells. Br J Haematol 2005; 131: 5966. 55 Shen L, Au WY, Guo T et al. Proteasome inhibitor bortezomib-induced apoptosis in natural killer (NK)-cell leukemia and lymphoma: an in vitro and in vivo preclinical evaluation. Blood 2007; 110: 46970. 56 Lee J, Suh C, Kang HJ et al. Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK T-cell lymphoma. Ann Oncol 2008; 19: 207983. 57 Yong W, Zheng W, Zhu J et al. L-asparaginase in the treatment of refractory and relapsed extranodal NK T-cell lymphoma, nasal type. Ann Hematol 2009; 88: 64752. 58 Zhang XX, Xie CH, Xu Y et al. Salvage treatment improved survival of patients with relapsed extranodal natural killer t-cell lymphoma, nasal type. Int J Radiat Oncol Biol Phys 2009; 74: 74752. 59 Murashige N, Kami M, Kishi Y et al. Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms. Br J Haematol 2005; 130: 5617. 60 Au WY, Lie AK, Liang R et al. Autologous stem cell transplantation for nasal NK T-cell lymphoma: a progress report on its value. Ann Oncol 2003; 14: 16736. 61 Lee J, Au WY, Park MJ et al. Autologous hematopoietic stem cell transplantation in extranodal natural killer T cell lymphoma: a multinational, multicenter, matched controlled study. Biol Blood Marrow Transplant 2008; 14: 135664. 62 Kim BS, Kim DW, Im SA et al. Effective second-line chemotherapy for extranodal NK T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone. Ann Oncol 2009; 20: 1218. 63 Nagato T, Kobayashi H, Kishibe K et al. Expression of interleukin-9 in nasal natural killer T-cell lymphoma cell lines and patients. Clin Cancer Res 2005; 11: 82507. 64 Jeon YK, Park CH, Kim KY et al. The heat-shock protein 90 inhibitor, geldanamycin, induces apoptotic cell death in EpsteinBarr virus-positive NK T-cell lymphoma by Akt down-regulation. J Pathol 2007; 213: 1709. 65 Coppo P, Gouilleux-Gruart V, Huang Y et al. STAT3 transcription factor is constitutively activated and is oncogenic in nasal-type NK T-cell lymphoma. Leukemia 2009; doi:10.1038/leu.2009.91.

2248

doi: 10.1111/j.1349-7006.2009.01319.x 2009 Japanese Cancer Association